Biomedicines,
Journal Year:
2022,
Volume and Issue:
10(10), P. 2667 - 2667
Published: Oct. 21, 2022
Recently,
a
fully
automated
instrument
for
the
detection
of
Cerebrospinal
Fluid
(CSF)
biomarker
Alzheimer’s
disease
(AD)
(low
concentration
Amyloid-beta
42
(Aβ42),
high
total
tau
(T-tau)
and
Phosphorylated-tau
(P-tau181)),
has
been
implemented,
namely
CLEIA.
We
conducted
comparative
analysis
between
ELISA
CLEIA
methods
in
order
to
evaluate
analytical
precision
diagnostic
performance
novel
system
on
111
CSF
samples.
Results
confirmed
robust
correlation
methods,
with
an
improvement
accuracy
new
methodology
single
biomarkers
their
ratio
values.
For
Aβ42
regression
Passing−Bablok
showed
Pearson
coefficient
r
=
0.867
(0.8120;
0.907%
95%
CI
p
<
0.0001),
T-tau
analysis:
0.968
(0.954;
0.978%
0.0001)
P-tau181:
0.946
(0.922;
0.962
5%
0.0001).
The
overall
ROC
AUC
comparison
more
accurate
automatic
method:
0.94
(95%
0.89;
0.99
vs.
0.95
1.00
P-tau181
0.91
0.85;
0.98
0.95;
method
automation
is
comparable
and,
P-tau181,
even
better,
as
compared
standard
ELISA.
Hopefully,
future,
could
be
useful
clinical
diagnosis
also
context
studies.
Cells,
Journal Year:
2023,
Volume and Issue:
12(9), P. 1309 - 1309
Published: May 4, 2023
Blood
biomarkers
have
been
considered
tools
for
the
diagnosis,
prognosis,
and
monitoring
of
Alzheimer’s
disease
(AD).
Although
amyloid-β
peptide
(Aβ)
tau
are
primarily
blood
biomarkers,
recent
studies
identified
other
reliable
candidates
that
can
serve
as
measurable
indicators
pathological
conditions.
One
such
candidate
is
glial
fibrillary
acidic
protein
(GFAP),
an
astrocytic
cytoskeletal
be
detected
in
samples.
Increasing
evidence
suggests
GFAP
levels
used
to
detect
early-stage
AD.
In
this
systematic
review
meta-analysis,
we
aimed
evaluate
peripheral
a
biomarker
AD
provide
overview
regarding
its
utility.
Our
analysis
revealed
level
was
higher
Aβ-positive
group
than
negative
groups,
individuals
with
or
mild
cognitive
impairment
(MCI)
compared
healthy
controls.
Therefore,
believe
clinical
use
measurements
has
potential
accelerate
diagnosis
improve
prognosis
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: March 14, 2024
Abstract
Liquid
biopsy,
which
is
a
minimally
invasive
procedure
as
an
alternative
to
tissue
has
been
introduced
new
diagnostic/prognostic
measure.
By
screening
disease-related
markers
from
the
blood
or
other
biofluids,
it
promises
early
diagnosis,
timely
prognostication,
and
effective
treatment
of
diseases.
However,
there
will
be
long
way
until
its
realization
due
conceptual
practical
challenges.
The
biomarkers
detected
by
liquid
such
circulating
tumor
cell
(CTC)
DNA
(ctDNA),
are
extraordinarily
rare
often
obscured
abundance
normal
cellular
components,
necessitating
ultra-sensitive
accurate
detection
methods
for
advancement
biopsy
techniques.
Optical
biosensors
based
on
nanomaterials
open
important
opportunity
in
because
their
enhanced
sensing
performance
with
simple
properties.
In
this
review
article,
we
summarized
recent
innovations
optical
demonstrate
sensitive
protein,
peptide,
ctDNA,
miRNA,
exosome,
CTCs.
Each
study
prepares
tailored
design
enhance
meet
requirements
each
biomarker.
unique
characteristics
metallic
nanoparticles
(NPs),
quantum
dots,
upconversion
NPs,
silica
polymeric
carbon
exploited
mechanisms.
These
advances
using
give
us
overcome
challenging
issues
provide
resource
understanding
unknown
well
mechanism
disease.
Graphical
abstract
Biosensors,
Journal Year:
2025,
Volume and Issue:
15(2), P. 85 - 85
Published: Feb. 4, 2025
Alzheimer’s
disease
(AD)
is
a
prevalent
neurodegenerative
disorder
and
significant
cause
of
dementia
in
elderly
individuals,
with
growing
prevalence
our
aging
population.
Extracellular
amyloid-β
peptides
(Aβ),
intracellular
tau
proteins,
their
phosphorylated
forms
have
gained
prominence
as
critical
biomarkers
for
early
precise
diagnosis
AD,
correlating
progression
response
to
therapy.
The
high
costs
invasiveness
conventional
diagnostic
methods,
such
positron
emission
tomography
(PET)
magnetic
resonance
imaging
(MRI),
limit
suitability
large-scale
or
routine
screening.
However,
electrochemical
(EC)
analysis
methods
made
progress
detection
due
sensitivity,
excellent
specificity,
portability,
cost-effectiveness.
This
article
reviews
the
EC
biosensing
technologies,
focusing
on
protein
blood
(a
low-invasive,
accessible
medium).
then
discusses
various
sensing
platforms,
including
fabrication
processes,
(LOD),
clinical
potential
show
role
these
sensors
transformers
changing
face
AD
diagnostics.
Biosensors,
Journal Year:
2023,
Volume and Issue:
13(7), P. 742 - 742
Published: July 17, 2023
Alzheimer's
disease
(AD)
is
the
most
common
neurological
and
a
serious
cause
of
dementia,
which
constitutes
threat
to
human
health.
The
clinical
evidence
has
found
that
extracellular
amyloid-beta
peptides
(Aβ),
phosphorylated
tau
(p-tau),
intracellular
proteins,
are
derived
from
amyloid
precursor
protein
(APP),
leading
biomarkers
for
accurate
early
diagnosis
AD
due
their
central
role
in
pathology,
correlation
with
progression,
diagnostic
value,
implications
therapeutic
interventions.
Their
detection
monitoring
contribute
significantly
understanding
advancing
care.
Available
techniques,
including
magnetic
resonance
imaging
(MRI)
positron
emission
tomography
(PET),
mainly
used
validate
diagnosis.
However,
these
methods
expensive,
yield
results
difficult
interpret,
have
side
effects
such
as
headaches,
nausea,
vomiting.
Therefore,
researchers
focused
on
developing
cost-effective,
portable,
point-of-care
alternative
devices
detect
specific
cerebrospinal
fluid
(CSF)
other
biofluids.
In
this
review,
we
summarized
recent
progress
electrochemical
immunosensors
detecting
(Aβ
p-tau
protein)
subtypes
(AβO,
Aβ(1-40),
Aβ(1-42),
t-tau,
cleaved-tau
(c-tau),
p-tau181,
p-tau231,
p-tau381,
p-tau441).
We
also
evaluated
key
characteristics
performance
developed
immunosensing
platforms,
signal
interfaces,
nanomaterials
or
amplifiers,
biofunctionalization
methods,
even
primary
sensing
performances
(i.e.,
sensitivity,
linear
range,
limit
(LOD),
application).
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(2), P. 1231 - 1231
Published: Jan. 19, 2024
Late-onset
Alzheimer’s
disease
is
the
leading
cause
of
dementia
worldwide,
accounting
for
a
growing
burden
morbidity
and
mortality.
Diagnosing
before
symptoms
are
established
clinically
challenging,
but
would
provide
therapeutic
windows
disease-modifying
interventions.
Blood
biomarkers,
including
genetics,
proteins
metabolites,
emerging
as
powerful
predictors
at
various
timepoints
within
course,
preclinical
stage.
In
this
review,
we
discuss
recent
advances
in
such
blood
biomarkers
determining
risk.
We
highlight
how
leveraging
polygenic
risk
scores,
based
on
genome-wide
association
studies,
can
help
stratify
individuals
along
their
profile.
summarize
studies
analyzing
protein
well
report
proteomic-
metabolomic-based
prediction
models.
Finally,
combination
multi-omic
potentially
be
used
memory
clinics
diagnosis
to
assess
dynamic
an
individual
has
developing
dementia.
Brain Sciences,
Journal Year:
2023,
Volume and Issue:
13(9), P. 1318 - 1318
Published: Sept. 14, 2023
Data
mining
involves
the
computational
analysis
of
a
plethora
publicly
available
datasets
to
generate
new
hypotheses
that
can
be
further
validated
by
experiments
for
improved
understanding
pathogenesis
neurodegenerative
diseases.
Although
number
sequencing
is
on
rise,
microarray
conducted
diverse
biological
samples
represent
large
collection
with
multiple
web-based
programs
enable
efficient
and
convenient
data
analysis.
In
this
review,
we
first
discuss
selection
associated
neurological
disorders,
possibility
combination
datasets,
from
various
types
samples,
conduct
an
integrated
in
order
achieve
holistic
alterations
examined
system.
We
then
summarize
key
approaches
studies
have
made
use
obtain
insights
into
translational
neuroscience
applications,
including
biomarker
discovery,
therapeutic
development,
elucidation
pathogenic
mechanisms
gap
bridged
between
improve
utilization
different
together
experimental
validation,
more
comprehensive
analyses.
conclude
providing
future
perspectives
integrating
multi-omics,
advance
precision
phenotyping
personalized
medicine
Frontiers in Neurology,
Journal Year:
2024,
Volume and Issue:
15
Published: Jan. 30, 2024
Purpose
This
study
aimed
to
evaluate
the
use
of
serum
neurofilament
light
chain
(NfL)
and
glial
fibrillary
acidic
protein
(GFAP)
in
diagnosis
Alzheimer’s
disease
(AD)
differential
between
AD
mild
cognitive
impairment
(MCI).
Methods
From
September
2021
October
2022,
we
collected
venous
blood
from
patients
healthy
individuals
who
visited
our
hospital’s
Neurology
Department,
isolated
detect
NfL
GFAP
using
direct
chemiluminescence.
The
results
were
analyzed
one-way
analysis
variance
(ANOVA)
receiver
operating
characteristic
(ROC)
curves.
Results
Pairwise
comparisons
among
three
groups
showed
that
compared
with
health
checkup
(HC)
group,
increased
both
MCI
(
P
<
0.05,
0.01).
There
significant
differences
groups,
level
group
was
higher
p
0.01),
while
there
no
difference
NfL.
Both
levels
can
independently
diagnose
ROC
curve
had
a
diagnostic
efficacy,
an
area
under
(AUC)
0.928.
cut-off
values
two
markers
for
>
40.09
pg./mL
>31.40
pg./mL.
Sensitivity
specificity
59.6
76.2%,
respectively,
GFAP,
they
90.4
82.1%,
respectively.
combined
improved
efficiency
(AUC
=
0.931,
sensitivity
78.8%,
92.3%).
value
46.05
Conclusion
be
used
as
biomarkers
AD.
Serum
has
better
efficacy
distinguish
MCI.
A
improve
specificity.
